Samsung Bioepis Co., Ltd. recalls HADLIMA (adalimumab-bwwd) injection
- Published
- 5 Nov 2025
- Units affected
- 5,518 packs (11,036 Syringes) 2 syringes/carton)
- Agency
- FDA
- Country
- United States
The hazard
Lack of Assurance of Sterility.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.
- Brand / company
- Samsung Bioepis Co., Ltd.
- Codes / lots
- Lot: F2505017, Expiry: 24-Jan-2027
- Distribution
- Distributed only to one warehouse in NJ. with no further distribution
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 5 Nov 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.